This is the authors' abstract. We don't add key points for this paper.
Background/Objectives: The bioavailability of crystalline vitamin B12 (B12) through active absorption is reported to have a maximum capacity of 1.5–2.5 µg per dose. A small passive bioavailability has also been suggested at high doses. The present study aimed to determine the dose-dependency of active B12 absorption and to quantify its passive absorption at higher doses. Methods: The dose-dependency of crystalline B12 bioavailability was determined in nine healthy adults, using oral [13C]-cyanocobalamin, in a cross-over design at doses of 2.5, 5, and 10 µg. The dose order was randomised, with a washout of one month. Literature data from was added to the present study data in a meta-analysis of the relation between B12 bioavailability and dose, to evaluate its pattern at different doses. Results: Bioavailability, as a function of dose, was significantly different between 2.5, 5, and 10 µg doses of [13C]-cyanocobalamin at 50.9 ± 32.5%, 26.7 ± 22.3%, 15.4 ± 13.6%, respectively, (p < 0.01), while the absolute bioavailability trended upward, at 1.16 ± 0.74 µg, 1.22 ± 1.02 µg, and 1.39 ± 1.23 µg (p = 0.46). The meta-analysis showed two distinct phases of bioavailability. Up to a dose of 2.6 µg, there was a significant steep positive correlation, with a slope (bioavailability) of 43%/µg suggesting an active process with a maximum of 1.2 µg. At higher doses, the slope was 1%/µg, not significantly different from zero, possibly a passive process. Conclusions: The active bioavailability of crystalline B12 is not dose-dependent, saturating at ~1.2 µg.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Kashyap et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: